Rudd P
Am J Med. 1986 May 23;80(5B):49-54. doi: 10.1016/0002-9343(86)90852-1.
The short-term antihypertensive efficacy and safety of terazosin when administered with a diuretic were assessed in three randomized, double-blind, placebo-controlled studies. In all studies, adding terazosin to an established diuretic regimen resulted in significant incremental decreases in blood pressure from baseline to the final visit, with an overall satisfactory response rate of 56 percent versus 29 percent for control subjects. Mean decreases in supine diastolic blood pressure in the terazosin-treated groups ranged from 4.5 to 8.9 mm Hg, compared with mean decreases of 0.4 to 5.8 mm Hg in the placebo-treated groups; these differences generally achieved statistical significance. There were no clinically or statistically significant changes in pulse rates, physical examinations, or electrocardiographic tracings. Results of clinical laboratory tests revealed no evidence of drug-induced toxicity. Patients receiving the terazosin plus diuretic combination had a slight tendency to gain weight. The most common adverse effects reported by this group were dizziness, headache, and asthenia. The results of these studies indicate that combination therapy with terazosin plus a diuretic is both safe and effective for the treatment of hypertension.
在三项随机、双盲、安慰剂对照研究中评估了特拉唑嗪与利尿剂联合使用时的短期降压疗效和安全性。在所有研究中，在既定的利尿剂治疗方案中添加特拉唑嗪，可使血压从基线到最后一次访视时显著逐步下降，总体有效率为56%，而对照组为29%。特拉唑嗪治疗组仰卧位舒张压的平均下降幅度为4.5至8.9毫米汞柱，而安慰剂治疗组为0.4至5.8毫米汞柱；这些差异通常具有统计学意义。脉搏率、体格检查或心电图记录均无临床或统计学上的显著变化。临床实验室检查结果未显示药物诱导毒性的证据。接受特拉唑嗪加利尿剂联合治疗的患者有轻微的体重增加倾向。该组报告的最常见不良反应为头晕、头痛和乏力。这些研究结果表明，特拉唑嗪加利尿剂联合治疗高血压既安全又有效。
